免疫介导性血栓性血小板减少性紫癜存活者沉默性脑梗死的危险因素
该研究纳入前瞻性NeST研究的前39例免疫介导性血栓性血小板减少性紫癜(iTTP)存活者,在临床缓解期行脑磁共振成像并以改良ARWMC评分量化沉默性脑梗死(SCI)负担。39例中20例(51.3%)存在SCI;多因素模型中较高的SCI负担与年龄较大、糖尿病、既往卒中、冠心病及诊断时峰值乳酸脱氢酶(LDH)升高显著相关,而血小板减少总天数与SCI负担无关。
要点
- 39例iTTP缓解期存活者中20例(51.3%)存在沉默性脑梗死(SCI)。
- 多因素模型中SCI负担与年龄较大、糖尿病、既往卒中、冠心病及峰值LDH升高显著相关。
- 血小板减少总天数(活动性iTTP天数的替代指标)与SCI负担无关。
核心结论
- 可改变与不可改变的因素共同参与iTTP存活者的SCI发生;作者认为缓解期对心血管合并症进行针对性管理可能减少长期神经系统后遗症;并指出需在更大队列中验证。
研究设计与样本
- 研究纳入前瞻性TTP神经系统后遗症(NeST)研究的前39例iTTP存活者,在临床缓解期行脑磁共振成像,并以改良年龄相关白质改变(ARWMC)评分量化SCI负担,采用多因素线性回归模型识别SCI负担的预测因素。
主要发现
- 39例参与者中20例(51.3%)存在SCI。
- 单因素分析中,较高的SCI负担与年龄较大、诊断iTTP时峰值血清肌酐升高、峰值乳酸脱氢酶(LDH)升高,以及包括糖尿病、既往卒中、冠心病(CAD)和脑血管病家族史在内的合并症相关。
- 多因素模型中,较高的SCI负担与年龄较大(p < 0.001)、糖尿病(p = 0.007)、既往卒中(p = 0.01)、CAD(p = 0.02)及峰值LDH升高(p = 0.046)显著相关。
- 血小板减少总天数(活动性iTTP天数的替代指标)与SCI负担无关。
临床怎么用
- 作者认为,缓解期对心血管合并症进行针对性管理可能减少iTTP存活者的长期神经系统后遗症。
局限性
- 原文指出需在更大队列中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) survivors are predisposed to silent cerebral infarctions (SCI) defined as radiological evidence of brain ischaemia without focal symptoms. This study examined risk factors associated with SCI burden in iTTP survivors during remission. We included the first 39 iTTP survivors enrolled in the prospective neurological sequelae of TTP (NeST) study. Participants underwent brain magnetic resonance imaging during clinical remission. SCI burden was quantified using the modified age-related white matter changes (ARWMC) score. Multivariate linear regression models identified the predictors of SCI burden. Of 39 participants, 20 (51.3%) had SCI. On univariate analysis, higher SCI burden was associated with older age, elevated level of peak serum creatinine and peak lactate dehydrogenase (LDH) during the index iTTP episode, comorbidities including diabetes mellitus, prior stroke, coronary artery disease (CAD) and family history of cerebrovascular disease. In the multivariate model, higher SCI burden was significantly associated with older age (p < 0.001), diabetes mellitus (p = 0.007), prior stroke (p = 0.01), CAD (p = 0.02) and elevated peak LDH (p = 0.046). Total days of thrombocytopenia (surrogate for 'days with active iTTP') were not associated with SCI burden. Both modifiable and non-modifiable factors contribute to SCI in iTTP survivors. Targeted management of cardiovascular comorbidities during remission may reduce long-term neurological sequelae. Validation in larger cohorts is needed.
引用
- Javed B, Yu J, Brown J, et al. Risk factors for silent cerebral infarction in immune-mediated thrombotic thrombocytopenic survivors. Br J Haematol. 2025. PMID: 41360721. doi:10.1111/bjh.70256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。